Vol.

No.

December 10, 2021Dec 10, 2021

DOWNLOAD THE PDF

A book draws on 50 years of accumulated wisdom, calls for “A New Deal for Cancer”

Cover Story

Cancer History Project Conversation with The Cancer Letter Free

A book draws on 50 years of accumulated wisdom, calls for “A New Deal for Cancer”

By Paul Goldberg

To accurately gauge the impact of the National Cancer Act of 1971 at the half-century point, Abbe R. Gluck and Charles S. Fuchs decided to focus on more than the science of cancer.

NCI Director's Report

Sharpless: NCI paylines to drop amid continuing resolution and federal budget uncertainty

By Matthew Bin Han Ong

Capitol Hill

Future of Biden’s ARPA-H murky as second CR delays FY22 appropriations

By Alice Tracey

Fox Chase gets three-year no-cost extension as director Fisher departs

By Paul Goldberg

Free In the Archives

A commitment to hope: Richard Nixon and the National Cancer Act

In Brief

Arif Kamal to join ACS as chief patient officer

$25M naming gift to Brown creates Legorreta Cancer Center

City of Hope to acquire Cancer Treatment Centers of America

E. Donnall Thomas’s Nobel Prize medal sells for $312,500

Case Comprehensive Cancer Center launches search for next director

Roman Skoracki named director of Ohio State’s Stefanie Spielman Comprehensive Breast Center

Melissa Simon, Sarki Abdulkadir, Mary Mulcahy take on Lurie Cancer Center senior leadership roles

VCU Health System opens $384M adult outpatient pavilion

NCCN summit explores ways to boost access to precision medicine

Miami Cancer Institute Summit of the Americas on Immunotherapies for Hematologic Malignancies scheduled for Jan. 21, 2022

ASTRO releases statement on RO Model delay in House Medicare provider relief bill

Sharon Wilks joins NEXT Oncology’s phase I clinical investigation team

Funding Opportunities

FDA OCE invites white papers for applied research funding

Clinical Roundup

Insights into T-cell exhaustion could improve cancer immunotherapies, Penn study finds

UK study identifies method of predicting treatment response in breast cancer

Researchers use genomics to match treatments to improved outcomes in metastatic breast cancer

Elacestrant may improve outcomes for patients whose metastatic breast cancers progressed on prior endocrine therapy

Breast cancer patients with ER mutations may benefit from early switch to Faslodex/Ibrance

Black women more likely to develop lymphedema following breast cancer treatment than white women

Studies show sustained benefits of Ayvakit in advanced systemic mastocytosis

Drugs & Targets

FDA approves Rituxan plus chemo for pediatric cancer indications

FDA approves FoundationOne CDx as companion diagnostic for BRAF inhibitor therapeutics in melanoma

FDA approves Cytalux for ovarian cancer imaging

FDA approves Oncomine Dx Target Test as CDx for Rybrevant

FDA accepts sBLA for BMS’ Reblozyl for priority review in adults with non-transfusion dependent beta thalassemia

M2GEN, Microsoft to collaborate on bioinformatics solutions for oncology

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 50 | Issue 46 - December 13, 2024